Conference Reports for NATAP

AASLD 61th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2010 Back

Phase I Study in Healthy Volunteers and Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase Inhibitor       Reported by Jules Levin AASLD Nov 2 2010 Boston   J. de Bruijne1, J. v.d. Wetering de Rooij2, A.A. van Vliet2, J.Leempoels3, X.J. Zhou4, C. Weegink1, R. Molenkamp1, J. Schinkel1, M.F. Temam4, J. Molles4, J. Chen4, K. Pietropaolo4, J.Z. Sullivan-Bólyai4, D. Mayers4 and H.W. Reesink1 1Academic Medical Center, Amsterdam, NL; 2Pharmaceutical Research Associates Group, Zuidlaren, NL; 3SGS Life Sciences, Antwerpen, BE, 4Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France. REFERENCES 1. Biello JP, Standring DN, Dousson C, et al (2008). Hepatology 48 Suppl. 1, 1166A-1167A.